Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Randomized Controlled Trial
. 2010 Sep 30;363(14):1324-34.
doi: 10.1056/NEJMoa0911123.

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Alice L Yu  1 , Andrew L Gilman, M Fevzi Ozkaynak, Wendy B London, Susan G Kreissman, Helen X Chen, Malcolm Smith, Barry Anderson, Judith G Villablanca, Katherine K Matthay, Hiro Shimada, Stephan A Grupp, Robert Seeger, C Patrick Reynolds, Allen Buxton, Ralph A Reisfeld, Steven D Gillies, Susan L Cohn, John M Maris, Paul M Sondel; Children's Oncology Group
Affiliations
Randomized Controlled Trial

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma (VSports)

Alice L Yu et al. N Engl J Med. .

VSports在线直播 - Abstract

Background: Preclinical and preliminary clinical data indicate that ch14. 18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14 VSports手机版. 18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14. 18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. .

Methods: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14. 18 in combination with alternating GM-CSF and interleukin-2) V体育安卓版. Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. .

Results: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2. 1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs V体育ios版. 46±5% at 2 years, P=0. 01) and overall survival (86±4% vs. 75±5% at 2 years, P=0. 02 without adjustment for interim analyses). .

Conclusions: Immunotherapy with ch14. 18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials VSports最新版本. gov number, NCT00026312. ) .

PubMed Disclaimer

Figures

Figure 1
Figure 1. Enrollment, Randomization, and Follow-up of the Study Patients
Patients receiving protocol therapy were still being treated with isotretinoin, with or without immunotherapy, at the time the data were analyzed.
Figure 2
Figure 2. Kaplan–Meier Estimates of Survival among the 226 Study Patients Who Had Been Randomly Assigned, According to Treatment Group
Data are shown for event-free survival (Panel A) and overall survival (Panel B) for all 226 patients and for event-free survival (Panel C) and overall survival (Panel D) for the 179 patients 1 year of age or older at enrollment. The estimated survival (±SE) at 2 years is indicated in each plot.
See this image and copyright information in PMC

Comment in

  • Antibody therapy and neuroblastoma.
    Tao X. Tao X. N Engl J Med. 2011 Jan 20;364(3):289; author reply 289-90. doi: 10.1056/NEJMc1012160. N Engl J Med. 2011. PMID: 21247330 No abstract available.

"V体育ios版" References

    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER★Stat mortality database: total US. Bethesda, MD: National Cancer Institute; 1969–2006.
    1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20. - PubMed
    1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165–73. - PubMed
    1. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s Oncology Group study. J Clin Oncol. 2009;27:1007–13. - "VSports注册入口" PMC - PubMed
    1. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984;44:5914–20. - PubMed

Publication types

MeSH terms

"VSports app下载" Associated data